This is Why Right Now is the Best Time to Buy Iovance Biotherapeutics

    Author Dylan BernhardtPosted on Categories Biotechnology, HealthcareTags , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
    Best Time to Buy Iovance Biotherapeutics

    Iovance Biotherapeutics Inc. (NASDAQ:$IOVA) is a huge mover this week as shares have increased 5.10%, or $0.4 during the last trading session. In total, about 568,977 shares have been traded, 39.85% up from the average.

    The company is a clinical-stage biopharmaceutical company, focusing on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. Currently, Iovance is reported negative earnings. The market cap is set at $517.16 million.

    Wall Street patiently awaits Iovance’s earnings release on November 3rd, with forecasted EPS to be $-0.35, down exactly $0.03 or 9.37% from 2014’s $-0.32 EPS.

    Featured Image: Depositphotos/© Ai825

    Author Dylan Bernhardt
    About the author: Dylan is a content writer and editor located in Vancouver, British Columbia. He graduated from the University of Regina with BA degrees in both Journalism and History in 2016. His skills include writing, blogging, editing, and developing content for both print and internet media.